AI Generated Image
Grandfather with pancreatic cancer beats the odds with clinical trial
Yahoo • • health
Key Points:
- Hernando Salcedo, an 83-year-old diagnosed with Stage III pancreatic cancer, initially experienced severe side effects from traditional chemotherapy, which greatly reduced his quality of life.
- Salcedo was enrolled in a clinical trial testing RenovoRX’s RenovoCath system, a catheter-based chemotherapy delivery device designed to target tumors more precisely and reduce systemic side effects.
- The RenovoCath system isolates the tumor's blood flow, delivering chemotherapy directly to the cancer site, resulting in fewer adverse effects and improved survival compared to standard intravenous chemotherapy.
- After switching to the catheter-based treatment, Salcedo reported feeling significantly better, with stable cancer progression and an improved quality of life, allowing him to participate in family events and resume normal activities.
- The RenovoCath device is FDA-cleared, with ongoing research expected to publish final trial results in late 2027, offering hope for extending life expectancy and maintaining quality of life in Stage III pancreatic cancer patients.
